Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways
This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essenti...
Συγγραφή απο Οργανισμό/Αρχή: | SpringerLink (Online service) |
---|---|
Άλλοι συγγραφείς: | Yarden, Yosef (Επιμελητής έκδοσης, http://id.loc.gov/vocabulary/relators/edt), Elkabets, Moshe (Επιμελητής έκδοσης, http://id.loc.gov/vocabulary/relators/edt) |
Μορφή: | Ηλεκτρονική πηγή Ηλ. βιβλίο |
Γλώσσα: | English |
Έκδοση: |
Cham :
Springer International Publishing : Imprint: Springer,
2018.
|
Έκδοση: | 1st ed. 2018. |
Σειρά: | Resistance to Targeted Anti-Cancer Therapeutics,
15 |
Θέματα: | |
Διαθέσιμο Online: | Full Text via HEAL-Link |
Παρόμοια τεκμήρια
-
Resistance to Targeted Therapies in Lymphomas
Έκδοση: (2019) -
Resistance to Tyrosine Kinase Inhibitors
Έκδοση: (2016) -
Targeting the DNA Damage Response for Anti-Cancer Therapy
Έκδοση: (2018) -
Resistance to Ibritumomab in Lymphoma
Έκδοση: (2018) -
Targeting Notch in Cancer From the Fruit Fly to the Clinic /
Έκδοση: (2018)